

☒

+

O I P E JC25
 MAR 11 2004
 PATENT & TRADE MARKS
 ADVISORY

Complete if Known

(use as many sheets as necessary)

1

of

2

10/734,787

12-12-2003

THIERRY CANTON, ET AL

Examiner Name

FRAV2002/0036 - US - NP

[illegible][illegible]

G. Karzish

9/26/06

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☒

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/734,787
				Filing Date	12-12-2003
				First Named Inventor	THIERRY CANTON, ET AL
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	FRAV2002/0036 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GK		FASSBENDER K., ET AL, Simvastatin Strongly Reduces Levels of Alzheimer's Disease Beta-Amyloid Peptides Abeta 42 and Abeta 40 in Vitro And In Vivo, Proceedings of the National Academy of Science of the United States of America (2001, Volume 98, Issue 10, pp. 5856-5861)	
		HARTMAN T., Cholesterol, Abeta and Alzheimer's Disease, Trends in Neuroscience (2001, Volume 24, Issue 11, pp. s45-s48)	
		REFOLO L. M., ET AL, A Cholesterol-Lowering Drug Reduces Beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease, Neurobiology of Disease (2001, Volume 8, Issue 5, pp. 890-899)	
GK		RODRIGUES C. M. P. ET AL, Amyloid B-Peptide Disrupts Mitochondrial Membrane Lipid And Proteinstructure, Biochemical and Biophysical Research Communications (2001, Volume 281, Issue 2, pp. 468-474)	

Examiner Signature	G. Kozish	Date Considered	9/26/06
-----------------------	-----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.